IL6 and Alzheimer disease: Consistently, our animal experiments demonstrate that, compared to the control group, the levels of gp130, IL‐6, and OSM are elevated in the serum and hippocampus of the AD group, indicating that increased levels of interleukin‐6 receptor subunit beta may influence the development of AD.